Please ensure Javascript is enabled for purposes of website accessibility

Md. biopharm gets 2 new neurodegenerative disorder treatment patents

Md. biopharm gets 2 new neurodegenerative disorder treatment patents

Listen to this article
(pressmaster / Depositphotos.com)
(pressmaster / Depositphotos.com)

Inc., a Germantown biopharmaceutical company working on treatments for nervous system diseases, was awarded two patents by the U.S. Patent and Trademark Office.

One patent covers ways of treating neurodegenerative disorders through transplantation of neural stem cells. The other covers neural stem cells engineered to express IGF-1, a molecule with potential in the treatment of neurodegenerative disorders.

Rich Daly, chairman and CEO of Neuralstem, said the patents provide additional protection for its platform.